The firm will begin selling its ThyGeNext thyroid cancer diagnostic tool to physicians in New York and Pennsylvania in combination with ThyraMir.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.
The tests have received coverage decisions from a number of Blue Cross Blue Shield plans this year including ones in California and New Jersey.
The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.
Under the new agreement, physicians can order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis.
The revenue growth was primarily driven by the company's two thyroid tests, which have been steadily gaining payor coverage.
Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.
In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.